AmpliPhi Bio Appoints Dr. Carrie-Lynn Langlais Furr As Vice President of Regulatory Affairs And Program Management

SAN DIEGO, October 17, 2016 – AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that Carrie-Lynn Langlais Furr, Ph.D., RAC, has been appointed as the Company’s Vice President of Regulatory Affairs and Program Management. In addition to more than 16 years of scientific expertise in bacteriophage, Dr. Furr brings over a decade of integrated product development and regulatory affairs experience to this new position at AmpliPhi. Prior to joining the Company, Dr. Furr served as Senior Director of Operations at Rho, Inc., a clinical research organization, where she also held leadership roles in regulatory affairs, integrated product development, program management and medical writing. Dr. Furr’s prior experience includes providing strategic and operational support throughout all phases of clinical development, including formal interactions and negotiations with regulatory authorities as well as submission of several biologics license applications and new drug applications with the U.S. Food and Drug Administration. She received a Ph.D. from Texas A&M University where she studied bacteriophage lifecycle and lysis mechanisms, biochemistry, and biophysics. M. Scott Salka, CEO of AmpliPhi Biosciences commented on the appointment: “Carrie-Lynn has a passion for the development of phage-based therapies and brings a wealth of product development and regulatory affairs knowledge and specialist skills to the Company. Her expertise will be especially valuable as we advance our lead programs through clinical development and increase our communications with regulatory agencies. We are delighted to welcome Carrie-Lynn to the AmpliPhi team.”